The rise of copyright’s blockbuster initially drove a surge for pharma, however recent changes present a uncertain picture for investors. Generic competitors are reducing earnings, and persistent patent challenges https://honeyqmri137805.ltfblog.com/39647651/sildenafil-and-big-pharma-a-risky-play